Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MCV4 (CRM197) in Adults 18-59 Years
NCT06226714Phase 3Active, not recruiting
- Sponsor
- CanSino Biologics Inc.
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of minoxidil + finasteride in meningococcal meningitis, sponsored by CanSino Biologics Inc.. Started Mar 2024; status: active, not recruiting.
02
Drugs
minoxidil + finasteride
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT06226714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226714.